Deciphering the Molecular Mechanism of the Small Molecule Myotrope Danicamtiv

Heart failure, a leading cause of mortality and morbidity worldwide, is characterized by the inability of the heart to generate sufficient power to perfuse the body at normal filling pressures. Current treatments for systolic heart failure prevent adverse remodeling of the heart, but they do not directly address the inability of the heart to generate power. Recently, there has been an interest in developing small molecules that directly modulate sarcomeric contractility for heart failure, two of which are omecamtiv mecarbil (OM) and danicamtiv.